Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Phase 3

Completed

Brief Summary: The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes commercially available, whichever comes first.

Detailed Description: Multiple sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. As a result, patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with MS. This study will evaluate the effects and possible risks of taking Fampridine-SR in MS patients over a long period of time.

Recruitment & Eligibility

Inclusion Criteria

Patient must have been previously enrolled in the Acorda Therapeutics MS-F204 study and received either Fampridine-SR or placebo
Patient with clinically defined multiple sclerosis (the diagnostic criteria based on: McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology. 2001; 50: 121-127)
Patient must be at least 18 years of age. Any patient who is now over the age of 70 must be in good overall health in the judgment of the investigator
Patient must be of adequate cognitive function, as judged by the Investigator
Patients who are women of childbearing potential must have a negative urine pregnancy test at the screening visit

Exclusion Criteria

Female patients who are either pregnant or breastfeeding.
Women of childbearing potential who are not using a specified birth control method
Patients discontinued prematurely from the MS-F204 study
Patients with a history of seizures or with evidence of past, or possible epileptiform activity on an EEG
Patient with either a clinically significant abnormal ECG or laboratory values at the MS-F204 EXT screening visit
Patient with severe renal impairment
Patient with angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator
Patient with a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet
Patient who has received an investigational drug (other than Fampridine-SR or placebo under MS-F204 study) within 30 days of the MS-F204EXT screening visit or a patient who is scheduled to enroll in an investigational drug trial at any time during this study
Patient who has a history of drug or alcohol abuse within the past year

Primary Outcome Measures

Name	Time	Method
Summary of Treatment Emergent Adverse Events (TEAE).	up to 40 months	All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.

Secondary Outcome Measures

Name	Time	Method
Timed 25-Foot Walk (T25FW)	Week 2, 14, 26, continuing every 26 weeks until the Final Visit
Subject Global Impression (SGI)	Visit 1 and every clinic visit thereafter (other than the follow-up visit)	For the SGI, the potential responses to the effects of the investigational drug during the preceding week were 1=terrible, 2=unhappy, 3=mostly dissatisfied, 4=neutral/ mixed, 5=mostly satisfied, 6=pleased, and 7=delighted.
Clinician's Global Impression (CGI)	Visit 1 and every clinic visit thereafter	The potential responses were 1=very much improved, 2=much improved, 3=somewhat improved, 4=no change, 5=somewhat worse, 6=much worse, and 7=very much worse.
Expanded Disability Status Scale (EDSS)	The Screening Visit, Visit 6, Final Visit or Early Termination Visit (if applicable)	The EDSS was used to grade patient disability on a scale from 0.0 (normal neurological exam) to 10.0 (death)

Locations (42): Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
🇺🇸
Phoenix, Arizona, United States
HOPE Research Institute
🇺🇸
Phoenix, Arizona, United States
Neurological Associates
🇺🇸
Fayetteville, Arkansas, United States
Alta Bates Summit Medical Center - Research and Education Institute
🇺🇸
Berkeley, California, United States
USC, Keck School of Medicine Health Care Consultation Center
🇺🇸
Los Angeles, California, United States
UC Davis
🇺🇸
Sacramento, California, United States
Yale University MS Center
🇺🇸
New Haven, Connecticut, United States
Shepherd Center
🇺🇸
Atlanta, Georgia, United States
University of Chicago
🇺🇸
Chicago, Illinois, United States
Consultants in Neurology, Ltd.
🇺🇸
Northbrook, Illinois, United States
Scroll for more (32 remaining)
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
🇺🇸Phoenix, Arizona, United States